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Summary: Immunotherapy leads to signiﬁcantly prolonged survival
of patients with metastatic melanoma. Autoimmune side eﬀects
including colitis, dermatitis, and endocrine abnormalities are
common in patients treated with ipilimumab [anti-CTLA4 (cyto-
toxic T-lymphocyte-associated protein 4)]. Antibodies such as
pembrolizumab that interfere with the PD-1 (programmed cell
death 1)/PD-L1 pathway show greater eﬃcacy and less toxicity
than ipilimumab. Here we report 2 cases of pembrolizumab-
induced uveitis associated with complete or partial tumor response.
We suggest that uveitis may serve as a surrogate marker for a
tumor response to therapy with pembrolizumab.
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BACKGROUND
Immunotherapy has dramatically improved the prog-
nosis of metastatic melanoma. Although ipilimumab, the
ﬁrst-in-class antibody targeting a lymphocyte inhibitory
receptor (checkpoint), showed a response rate of around
10%–15%, it can lead to life-threatening autoimmune
adverse events.1,2 Programmed cell death 1 (PD-1)-speciﬁc
antibodies, including pembrolizumab, demonstrate greater
eﬃcacy and less toxicity than compared with ipilimu-
mab.3–5 According to common toxicity criteria version 4.0
(CTCAE 4.03), uveitis is a very rare side eﬀect occurring in
approximately 1% of patients treated with pem-
brolizumab.3 Recently, 2 case reports showed that uveitis
can lead to grade 3–4 toxicity.6,7 Uveitis was described
several years ago as a frequent adverse eﬀect of adoptive T-
cell transfer of in vitro-expanded tumor-inﬁltrating lym-
phocytes and is associated with strong immune responses
and tumor responses in melanoma patients.8,9
PRESENTATION OF 2 CASES
Patient 1
A 60-year-old patient was diagnosed with BRAF wild-type
metastatic melanoma in January 2015, without any primary tumor.
Imaging studies showed disseminated pulmonary and lymph node
metastases (Fig. 1A). First-line treatment with the anti-CTLA4
antibody ipilimumab was started. After 3 cycles without signs of
toxicity, a CT scan revealed progressive disease with new liver
metastases (Fig. 1B). Treatment was switched to pembrolizumab with
FIGURE 1. Kinetics of lung metastasis before immunotherapy
was started (A), after 3 cycles of ipilimumab (B), and at the time
point when the patient developed uveitis for the first time (C).
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the approved standard protocol of 2mg/kg every 3 weeks. Restaging
after 3 months showed a partial tumor remission without any adverse
events (Fig. 1C). Pembrolizumab was continued with the same
schedule until the patient underwent elective unilateral cataract sur-
gery on the right eye. Within a week, the patient developed bilateral
vision problems.
Eye examination showed signs of endophthalmitis with
anterior chamber cells in both the right (operated) and left eyes,
reduced acuity of vision, and macular edema (Fig. 2A). The patient
has had no past medical history of uveitis. Pembrolizumab was
stopped and topical treatment with steroids and antibiotics was
started. Oral steroids were added and the inﬂammation regressed,
with concurrent improvement of visual acuity. The systemic ste-
roids were tapered without exacerbation. Despite treatment with
pembrolizumab having been interrupted, a follow-up CT scan
showed an ongoing partial response and pembrolizumab was
restarted. Within days, the patient again developed bilateral visual
problems and, once again, bilateral posterior uveitis (grade 3
according to CTCAE 4.03) including cystoid macular edemas
(Figs. 2B, C).
Systemic steroids were started. Despite immediately stopping
pembrolizumab therapy, the most recent CT scan 6 months later
showed ongoing partial tumor response.
Patient 2
A 75-year-old man, with stage IV metastatic melanoma,
showed progressive disease under ipilimumab and experimental
targeted therapy (encorafenib, binimetinib, and LEE011, clinical-
trials.gov NCT01543698) before his treatment was switched to
pembrolizumab 2mg/kg. At the baseline examination before
starting the treatment, he presented with bilateral signs of a pre-
viously unnoticed uveitis with pupillary adhesions. In the context
of this clinical study he underwent regular ophthalmic examinations,
including optical coherence tomography (OCT). After 8, 24, and 32
FIGURE 2. Cystoid macular edema after cataract surgery on the right eye. A, Horizontal optical coherence tomography scan centered
on the fovea; edema of all retinal layers is present, a subfoveal central serous neuroretinal detachment has developed, and there are
large cystic lesions in several inner layers. B, Recurrence of edema after restarting pembrolizumab. Slit-lamp pictures prove signs of
bilateral uveitis of the anterior segment 2 months after treatment. C, The right eye with intraocular lens and giant cells. D, The left eye
with posterior synechiae and cataract.
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weeks, he experienced 3 relapses of bilateral and mostly anterior
uveitis with precipitates on the endothelium and iris border, haze, and
cellular inﬁltration. There was only minimal vitreous involvement.
Under topical treatment with nepafenac, prednisolone acetate, and
scopolamine the inﬂammation resolved within 2–3 weeks. Following
discussion and consideration of this event, the patient consented to a
FIGURE 3. Cystoid macular edema during a relapse of bilateral uveitis with posterior-segment involvement after ipilimumab and MEK-
inhibitor pretreatment. A, Left: scanning laser ophthalmoscopy (SLO) of the right eye shows a blunted foveal region (arrow) and
reduced signals due to vitreous infiltration; Right: horizontal line scan with optical coherence tomography (OCT) confirms 1 large and
several smaller cysts (arrow) in the inner retinal layers and deformation of the foveal contour. B, One week later, after intensive topical
treatment, the patient had no symptoms and almost normal visual acuity. Right: the SLO image is even more shaded due to increased
cellular infiltration (asterisk) of the vitreous; left: OCT scan shows shrinkage of the cyst (arrow). C, Two months later, the inflammation
had recovered completely. Right: on SLO the vitreous has cleared; left: the horizontal scan at the same position reveals that the foveal
contours have returned to normal and all cysts have disappeared.
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second course of immunotherapy with pembrolizumab as the
potential beneﬁts outweighed the risks. We prescribed prophylactic
instillation of nepafenac drops and planned ophthalmic checks after
each infusion. As the patient did not experience eye symptoms, he
spontaneously discontinued the self-administration of the drops.
Three days later, following the fourth infusion in week 8, clinical
examination showed mild eye changes with cells in the anterior
chamber. We instructed the patient to continue treatment and added
prednisolone eye drops. In week 13, he complained of visual dis-
turbances for the ﬁrst time and ophthalmologic examination showed
involvement of the posterior eye segment with cystoid macular edema
(Fig. 3A). Intensive topical treatment with steroids, mydriatics, and
NSAIDs was started and continued over 2 months. A combination of
a b-blocker and a carbonic anhydrase inhibitor, Cosopt (timolol and
dorzolamide), had to be prescribed to lower the intraocular pressure.
In the course of this intensiﬁed topical regimen the patient recovered
without functional sequelae (Figs. 3B, C). We were able to continue
treatment with pembrolizumab without interruption. During the
course of treatment, the patient also developed a skin rash. Skin
biopsy revealed a lichenoid reaction pattern, which is commonly seen
during anti-PD-1 therapy in melanoma patients. We interpreted the
rash as an adverse drug reaction and successfully treated it with
topical steroids.
A subsequent PET-CT scan revealed complete regression of
the previously described tumor metastasis in the lower lobe of the
left lung. Treatment and regular follow-ups are currently ongoing.
DISCUSSION
Uveitis is classiﬁed according to the anatomic site of the
inﬂammation in the eye as either anterior, intermediate or
posterior uveitis, or panuveitis. The etiology is mostly infective
(eg, toxoplasmosis), but can also be autoimmune (eg,
HLAB27-associated uveitis). Uveitis is one of the most com-
mon reasons for legal blindness.10 In patients treated with anti-
PD-1 antibodies, uveitis is described as a comparatively rare
side eﬀect.3,7 Treatment includes the application of topical
steroids and systemic steroids for higher CTCAE 4.03 grades.
Most authors describe immunotherapy-associated uveitis to be
a toxic eﬀect. In our point of view, immunotherapy-induced
uveitis should not only be considered as toxicity but also as the
manifestation of an immune response.
On the basis of the literature and our 2 case reports, we
would like to outline 3 possible conclusions: ﬁrstly, we
suggest that patients have ophthalmological examinations,
including OCT, before the start of immunotherapy and
regular opthalmological follow-up during the treatment.
Secondly, similar to vitiligo, uveitis may be considered a
surrogate marker for the eﬃcacy of immunotherapy. Sight-
threatening cystoid macular edema needs potent treatment,
including systemic steroids if needed. Regular OCT
examinations in patients at risk help to diagnose this dan-
gerous complication early. However, this adverse event may
not initially require high-dose systemic steroids. Rather, we
would implement an active surveillance strategy, that is,
patients should be monitored closely and given topical
NSAIDs prophylactically if they have a history of or are
prone to develop uveitis. Steroid drops should be used at
the slightest sign of active inﬂammation. The prophylactic
and therapeutic measures should be taken generously over
many months.8,11,12 Finally, the ﬁrst of our 2 cases dem-
onstrates that care is needed with elective surgery in
patients undergoing immunotherapy. Presumably, the cat-
aract surgery triggered bilateral uveitis in this patient. Both
PD-1/PD-L1 and CTLA4 axes (checkpoints) are mecha-
nisms to prevent autoimmunity and continued immune
destruction (immune pathology) in ongoing disease. The
immune privilege of the eye depends partly on the outer
blood-retinal barrier of the pigment epithelium. In patients
treated with MEK inhibitors, retinopathy with a presumed
dysfunction of the pigment epithelium is frequently
observed. Therefore, any tissue injury and its biological
repair can potentially attract or reactivate immune cells that
may subsequently be ampliﬁed with checkpoint inhibitors
and cause collateral tissue damage.
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